Bringing Insights to Life

Interpace Biosciences® (IDXG) is a dynamic and growing leader in the life sciences industry, providing complex molecular analysis for the early diagnosis and treatment of cancer.

Learn More

IMPORTANT INFORMATION

Specimens and Orders for PancraGEN® and Fluid Chemistry Testing Will Not Be Accepted After May 2, 2025.

Interpace will continue to offer ThyGeNEXT®+ThyraMIR®v2 testing for indeterminate thyroid nodules without interruption.

View Details

Latest News

Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk

Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results

PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan
View all news

Sign up for Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign up today

Stock Information

Day Range
52 Week Range
View Investor Relations